RA Capital Management

Eliem Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, dedicated to developing innovative therapeutic drugs for hyperexcitability disorders affecting the nervous system. Founded in 2018, the company focuses on creating treatments for conditions such as chronic pain, depression, epilepsy, and anxiety, which significantly impact the quality of life for millions. Eliem employs its expertise in neuroscience and translational medicine to advance a promising pipeline of drug candidates, aiming to address unmet medical needs in these areas. Notably, its leading drug candidate, ETX-155, targets major depressive disorder and focal onset seizures. Through its efforts, Eliem Therapeutics seeks to improve the lives of patients suffering from these debilitating disorders.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, that focuses on drug discovery through its innovative platform targeting solute carrier (SLC) transporters. Established in 2016, the company aims to improve patient outcomes by developing small molecule therapies for various diseases, including those related to immunometabolism, lysosomal function, and mucosal defense. By utilizing advanced chemoproteomics techniques, Jnana accelerates the identification of therapeutic targets, addressing significant unmet medical needs in areas such as immuno-oncology, inflammatory disorders, and neurological diseases. The company's approach seeks to enhance drug discovery efficiency by comprehensively targeting the vast family of membrane proteins associated with SLC transporters.

HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines. HilleVax was founded in 2021 and was headquartered in Boston, Massachusetts.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, that focuses on drug discovery through its innovative platform targeting solute carrier (SLC) transporters. Established in 2016, the company aims to improve patient outcomes by developing small molecule therapies for various diseases, including those related to immunometabolism, lysosomal function, and mucosal defense. By utilizing advanced chemoproteomics techniques, Jnana accelerates the identification of therapeutic targets, addressing significant unmet medical needs in areas such as immuno-oncology, inflammatory disorders, and neurological diseases. The company's approach seeks to enhance drug discovery efficiency by comprehensively targeting the vast family of membrane proteins associated with SLC transporters.

Eliem Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, dedicated to developing innovative therapeutic drugs for hyperexcitability disorders affecting the nervous system. Founded in 2018, the company focuses on creating treatments for conditions such as chronic pain, depression, epilepsy, and anxiety, which significantly impact the quality of life for millions. Eliem employs its expertise in neuroscience and translational medicine to advance a promising pipeline of drug candidates, aiming to address unmet medical needs in these areas. Notably, its leading drug candidate, ETX-155, targets major depressive disorder and focal onset seizures. Through its efforts, Eliem Therapeutics seeks to improve the lives of patients suffering from these debilitating disorders.

Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novel antibody-based immunotherapies. It was founded in 2019 and is based in Boston, Massachusetts.

Eliem Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, dedicated to developing innovative therapeutic drugs for hyperexcitability disorders affecting the nervous system. Founded in 2018, the company focuses on creating treatments for conditions such as chronic pain, depression, epilepsy, and anxiety, which significantly impact the quality of life for millions. Eliem employs its expertise in neuroscience and translational medicine to advance a promising pipeline of drug candidates, aiming to address unmet medical needs in these areas. Notably, its leading drug candidate, ETX-155, targets major depressive disorder and focal onset seizures. Through its efforts, Eliem Therapeutics seeks to improve the lives of patients suffering from these debilitating disorders.

Akouos, Inc. is a biotechnology company based in Boston, Massachusetts, dedicated to developing gene therapies aimed at restoring, improving, and preserving hearing for individuals affected by various inner ear disorders. Founded in 2016, the company utilizes an innovative platform that includes a proprietary adeno-associated viral vector library and a unique delivery method. Its leading product candidate, AK-OTOF, targets hearing loss resulting from mutations in the OTOF gene. Akouos focuses on genetically-defined patient populations, addressing conditions ranging from single genetic mutations to hearing loss caused by ototoxic drugs and aging. The company has established strategic partnerships with key institutions, including Massachusetts Eye and Ear and Lonza, Inc., to advance its mission of providing precision genetic therapies for sensorineural hearing loss.

Eliem Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, dedicated to developing innovative therapeutic drugs for hyperexcitability disorders affecting the nervous system. Founded in 2018, the company focuses on creating treatments for conditions such as chronic pain, depression, epilepsy, and anxiety, which significantly impact the quality of life for millions. Eliem employs its expertise in neuroscience and translational medicine to advance a promising pipeline of drug candidates, aiming to address unmet medical needs in these areas. Notably, its leading drug candidate, ETX-155, targets major depressive disorder and focal onset seizures. Through its efforts, Eliem Therapeutics seeks to improve the lives of patients suffering from these debilitating disorders.